Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20290463 | 0.82 | L3MBTL1 (0.51) | ALDH1A1MAPK1L3MBTL1KMT2A | |
| SCHEMBL5303102 | 0.75 | CYP2C19 (0.71) | CNR1GAATSHRCYP2C19LMNA | |
| SCHEMBL10246211 | 0.71 | BACE1 (0.44) | ALDH1A1GAATSHRCYP2C19APP | |
| SCHEMBL10131744 | 0.70 | LMNA (0.51) | ALDH1A1CNR1LMNAKMT2A | |
| SCHEMBL10131458 | 0.68 | CNR1 (0.38) | ALDH1A1CNR1LMNAKMT2A | |
| SCHEMBL4237258 | 0.67 | ALDH1A1 (0.56) | ALDH1A1GAATSHRCYP2C19APP | |
| SCHEMBL24133231 | 0.65 | TSHR (0.37) | ALDH1A1TSHRCYP2C19LMNA | |
| SCHEMBL3970286 | 0.63 | CNR1 (0.36) | CNR1 | |
| SCHEMBL3126654 | 0.62 | POLB (0.52) | ALDH1A1KDM4ETSHRCYP2C19LMNA | |
| SCHEMBL3968265 | 0.62 | CNR1 (0.39) | ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-7524842-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524842-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | ALDH1A1 1372/4885CNR1 1743/4885KDM4E 4550/4885 |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | ALDH1A1 1372/4885CNR1 1743/4885KDM4E 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.